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Abstract
Background: The ventricular septal defect (VSD) is the most common form of congenital heart defects. The purpose of this 
study was to evaluate the results of the early complications and mid-term follow-up of the transcatheter closure of the VSD 
using the Amplatzer VSD Occluder.
Methods: Between April 2012 and October 2013, 110 patients underwent the percutaneous closure of the perimembranous 
VSD. During the procedure, the size and type of the VSD were obtained via ventriculography. A device at least 2 mm larger 
than the VSD diameter measured via ventriculography was deployed. The size of the VSD, size of the Amplatzer, and device-
size to VSD-size ratio were calculated. After the confirmation of the suitable position of the device via echocardiography 
and left ventriculography, the device was released. Follow-up evaluations were done at discharge as well as at 1, 6, and 12 
months and yearly thereafter for the VSD occlusion and complete heart block.
Results: The study population comprised 62 females and 48 males. The mean age and weight of the patients at procedure 
were 4.3 ± 5.6 years (range: 2 to 14) and 14.9 ± 10.8 kg (range: 10 to 43). The average device size was 7.0 ± 2.5 mm (range: 4 
to 14). The VSD occlusion rate was 72.8% at the completion of the procedure and rose up to 99.0% during the follow-up. The 
most serious significant complication was complete atrioventricular block, which was seen in 2 patients. The mean follow-up 
duration was 10.9 ± 3.6 months.
Conclusion: The transcatheter closure of the perimembranous VSD was a safe and effective treatment with excellent 
closure rates in our study population. This procedure had neither mortality nor serious complications. 
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Introduction
The ventricular septal defect (VSD) is the most common 
form of congenital heart defects. It constitutes approximately 
30% of all congenital heart diseases.1, 2 With the advent 
of echocardiography and increasing experience of the 
operators, the recognition of the VSD has increased to 5 
/ 1000 live births.3, 4 Multifactorial and genetic causes are 
postulated to be responsible for the creation of the VSD. 
It is the most common congenital heart disease associated 
with trisomy 21, 13, and 18. For the description of the VSD, 
multiple classifications have been proposed. In the simplest 
classification, the VSD is divided into perimembranous, 
muscular, and inlet types. Small VSDs have neither 
significant pulmonary overload nor overcirculation. Medical 
treatment, surgical therapy, and percutaneous closure of 
these small defects are not suggested, and the outcome of 
these patients is excellent. For moderate or larger defects 
that result in an increased pulmonary flow, the surgical or 
interventional approach is recommended. 
The Amplatzer VSD Occluder was added to the 
interventional cardiology armamentarium in 1999.5, 6 The 
Amplatzer Membranous VSD Occluder is an asymmetrical 
double-disc device that was first described for the closure 
of membranous defects in 2000 and had its first clinical 
experience published in 2002.7, 8 The salient advantages of 
the use of this device are shorter hospital stay and avoidance 
of sternotomy and cardiopulmonary bypass. One of the 
most serious complications of this method, however, is 
the creation of atrioventricular conduction block (AVB). 
The follow-up studies of the patients who have had VSD 
closure with the Amplatzer VSD Occluder are limited to 
fewer than 10 years, in contrast to the surgical approach, 
which is now approaching to more than 60 years. Early 
and delayed AVBs have been described in fewer than 1% 
of patients after the surgical closure of the isolated VSD, 
whereas this complication ranges from 3% to 20% after the 
interventional approach and percutaneous closure.7-9 The 
immediate and short-term results of the transcatheter closure 
of the VSD with the Amplatzer VSD Occluder have been 
well documented.10, 11 
We sought to evaluate the early and mid-term follow-up 
results of the transcatheter closure of the VSD using the 
Amplatzer VSD Occluder in children.    
Methods
The study protocol was approved by the Ethics Committee 
of Iran University of Medical Sciences. In this prospective 
study, all patients scheduled for the transcatheter closure 
of the VSD between April 2012 and October 2013 in 
Rajaie Cardiovascular, Medical, and Research Center 
were included. There were 110 patients, comprised of 
62 females and 48 males. Written informed consent was 
obtained from the patients’ parents after they were provided 
with a comprehensive explanation about the procedural 
details and the advantages and possible complications. 
The patients were examined in accordance with a standard 
echocardiographic protocol. All the patients underwent 
transthoracic echocardiography (TTE), performed with a GE 
Vivid 3 machine. TTE included M-mode, two-dimensional, 
and color Doppler examinations. The standard technique 
was used to obtain the measurements in a quiet, wakeful, and 
non-sedated state for the older children and a sedated state 
for the younger children. The ejection fraction was estimated 
using M-mode and Simpson in the parasternal long- and 
short-axis views as well as in the apical four-chamber view, 
with two-dimensional and color Doppler being employed in 
all the views. The size and type of the VSD were examined 
in the standard four-chamber, five-chamber, and parasternal 
long- and short-axis views. 
The criterion for inclusion in our study was the 
echocardiographic or clinical evidence of a significant left-
to-right shunt through the VSD (> 1.5 / 1). A significant 
left-to-right shunt was considered to be a VSD, and one 
or more of the following data were found: 1) prominent 
cardiomegaly on standard chest X-ray; 2) left atrial 
enlargement, defined as a left atrial to aortic ratio > 1.5 in the 
long-axis parasternal view examination; 3) left ventricular 
overload and enlargement in echocardiography, defined as a 
left ventricular end-diastolic diameter ≥ 2 standard deviation 
(SD) for the body surface area; and 4) symptoms, including 
frequent respiratory infections (six events during a year) and/
or failure to thrive. Infants were selected for transcatheter 
VSD closure if they had a minimal weight of 10 kg. The 
exclusion criteria were as follows: 1) VSD associated 
with any other congenital heart disease which could be 
corrected surgically; 2) significant cardiac and non-cardiac 
comorbidities and anomalies that could impact the clinical 
outcome of the VSD closure as well as evidence of severe 
and prolonged congestive heart failure (After modifying the 
underlying diseases of these patients and medical treatment, 
we enrolled them in the study.); 3) VSDs with severe 
pulmonary artery hypertension and a right-to-left shunt or 
pulmonary vascular resistance > 8 Woods units; 4) weight 
< 10 kg; 5) perimembranous VSDs closer than 5 mm to the 
aortic valve and prolapse of an aortic cusp; 6) sepsis; and 7) 
contraindication to antiplatelet therapy. 
The percutaneous closure of the VSD was performed under 
general anesthesia. Only the first-generation VSD Occluder 
was used in our study. The femoral vein and the arterial line 
were obtained. The patients were given 100 IU/kg of heparin 
in two divided doses (50 IU/kg first and 50 IU/kg half hour 
later) to maintain an activated clotting time > 200 seconds 
after the catheterization of the femoral artery. Prophylactic 
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intravenous antibiotic with 30 mg/kg of cefazolin was 
administrated at the beginning of the procedure and by two 
subsequent doses every 8 hours during the following 24 
hours. The procedure was performed under fluoroscopic 
and TTE control. Previously we had used transesophageal 
echocardiography (TEE) for our procedures; however, 
our further experience led us to utilize TTE for the VSD 
closure. Standard right and left cardiac catheterization and 
angiography were performed. During the cardiac procedure, 
angiographic and catheterization data, including the size and 
type of the VSD and its position to the aorta, were obtained 
via ventriculography in the left anterior oblique (LAO) 
cranial view in different degrees and the right anterior 
oblique (RAO) view. The prolapse of the aortic cusps was 
identified via LAO aortography in the ascending aorta. The 
right ventricular pressure, pulmonary artery pressure, and 
fluoroscopy time were identified via right and left cardiac 
catheterization. 
A device at least 2 mm larger than the VSD diameter 
measured by ventriculography was chosen. Totally, 28 
Amplatzer Ductal Occluders and 82 Muscular VSD Occluders 
were used for the closure of the perimembranous VSDs. The 
other VSDs, i.e. apical or muscular VSDs, are not discussed 
here. Subsequently, a 0.035-inch Terumo Glide Wire was 
placed across the VSD using a 4- or 5-French curved end-
hole catheter (Judkins Right Coronary Catheter, Cobra) 
from the left ventricle into either branch pulmonary artery 
or superior or inferior vena cava. The next step was to snare 
the wire and exteriorize it to the femoral vein and establish 
an arteriovenous loop. Over this wire, an appropriately sized 
delivery sheath was advanced from the femoral vein by the 
standard protocol all the way until the tip of the sheath was 
in the descending aorta. Thereafter, in order to measure the 
VSD diameter, a ventriculogram in the best possible view 
was obtained. The device was loaded under a blood/saline 
mixture. The device was, subsequently, attached to the 
delivery sheath and advanced to the tip of the sheath during 
fluoroscopy. The device was deployed in accordance with 
the standard protocol in the VSD, and ventriculography was 
done. After the confirmation of the suitable position of the 
device by echocardiography and left ventriculography, the 
device was released. 
Complete blood cell count and chest X-ray were performed 
4-6 hours later to detect early complications such as occult 
bleeding and pulmonary complications. Additionally, an 
echocardiographic examination was performed to rule out 
pericardial effusion. Urine analysis to exclude hemolysis 
was done the day after the procedure. Vital signs monitoring 
was conducted during the first 24 hours. Moreover, 24-hour 
electrocardiographic (ECG) Holter was done the day after 
the procedure for dysrhythmia and heart block evaluation. 
All the patients received 1 mg/kg of clopidogrel for 3 days 
and 0.5 mg/kg for one month, 3 mg/kg of Acetylsalicylic 
Acid (ASA) for 6 months, and 50 IU/kg of heparin every 
6 hours for the first day. All the patients were discharged 
after ECG Holtering. Endocarditis prophylaxis was done for 
6 months if necessary and was discontinued at 6 months’ 
follow-up if the defect was completely occluded. ECG was 
done in routine visits at follow-up. All the patients had 
complete TTE studies before discharge as well as at 1, 6, and 
12 months and then yearly thereafter.
The data are expressed as frequencies or percentages 
for the nominal variables. The continuous variables are 
expressed as mean ± SD. For the statistical analyses, the 
statistical software SPSS version 18.0 for Windows (SPSS 
Inc., Chicago, IL) was used.
Results
Table 1 depicts the demographic, general, clinical, and 
analytical data of the patients. The clinical characteristics of 
the patients, e.g. age, sex, and weight, were recorded.
During the study, with the intention to close the VSD 
percutaneously, all the patients who had the inclusion criteria 
were sent to our catheterization laboratory. The defects 
were successfully closed in 109/110 (99.09%) patients. 
Device embolization occurred in none of the patients. In 
one patient during the procedure, approximately 10 cm of 
the distal segment of the wire was broken in the aortic arch 
and this segment was embolized into the carotid artery. 
After this section was effectively re-snared via the arterial 
line, the VSD closure was performed successfully. In 2 
patients, the devices were too small to close the defect and 
during the procedure the devices were pushed into the right 
ventricle; therefore, larger devices were implanted. We had 
no mortality in our study. One patient had complete heart 
block during the procedure, which could not be reversed by 
conservative treatment. In this patient, the defect was not 
closed; however, the device was excluded and the patient was 
referred for surgical correction. This patient had the lowest 
weight among our patients. One patient had complete heart 
block 2 weeks later: for this patient, pacemaker implantation 
was performed. Complete heart block did not occur any 
more in our study patients during the follow-up period. 
We had no major arterial complications such as massive 
bleeding or femoral arteriovenous fistula in our study. Mild 
thrombosis of the right or left femoral arteries and weak 
pulse occurred in 10 patients after the procedure. Heparin 
infusion was used successfully in 8 patients during the 
first 24 postprocedural hours; the patients’ pulses returned 
to normal during the first hours. Streptokinase intravenous 
infusion conferred a successful and complete turn of pulse 
without sequel in the other 2 patients. None of the patients 
needed further treatment or femoral artery thrombectomy. 
In all the patients, 5-French sheaths for the arterial lines 
and different sizes for the venous lines were used. All of 
these patients were less than five years old and weighed 
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Table 1. Patients characteristics*
Variant All Patients (n=110) Male (n=48) Female (n=62)  Range (All Patients)
Age (y) 4.3±5.6 5.2±6.7 3.4±4.8 2-14
Weight (kg) 14.9±10.8 16.3±14.2 14.2±13.2 10-43
VSD size (mm) 4.7±1.8 4.6±1.6 4.9±1.8 3.1-7.2
PA pressure  (mm Hg)
Systolic 31.3±14.2 34.2±16.1 30.2±12.1 20-57
Diastolic 16.2±8.4 17.8±9.2 15.3±7.1 10-40
Mean PA pressure (mm Hg) 22.6±6.4 25.2±7.1 21.6±6.5 14-45
Qp/QS 2.3±0.7 2.1±0.9 2.4±0.8 1.7- 4.8
Fluoroscopy time (min) 14.4±9.7 15.1±10.1 14.9±9.4 7.8-35.0
Total angiography time (min) 42.0 ±12.3 42.5±12.7 41.1±11.9 31-70
Size of Amplatzer (mm) 7.0±2.5 7.1±2.3 6.8±2.8 4–14
VSD size at ventriculogram 5.2±2.3 5.6±2.5 5.0±2.1 3-12
Device size/VSD size ratio 1.2±0.3 1.3±0.4 1.1±0.3 1.1-1.7
*Data are presented as mean±SD or minimum-maximum
VSD, Ventricular septal defect; QP/QS, Pulmonary blood flow to systemic blood flow; PA, Pulmonary artery 
less than 15 kg. Seven patients had a small second VSD in 
addition to the first defect; following device implantation, 
6 of these patients had no residue and one patient had mild 
residue at follow-up. In 9 patients, transient arrhythmias 
such as tachycardia, bradycardia, and bundle branch block 
developed during different maneuvers of the catheter or 
the wire. The procedure was stopped in these patients, and 
sinus rhythm quickly returned in all of them. None of our 
patients developed infectious endocarditis, and no mortality 
was reported. The left ventricular dimensions returned to 
normal in all the patients. In the patients with failure to 
thrive, their growth returned to the normal pattern. Patients 
with recurrent pneumonia had no significant recurrences. 
Follow-up at these time points (i.e. one month to 24 months) 
showed no significant complications such as new aortic 
regurgitation, device embolization or malposition, thrombus 
or clot formation, hemolysis, and thromboembolism. 
Angiography at the end of the procedure demonstrated 
complete occlusion in 72.8% of the patients immediately 
after the completion of the procedure; it rose up to 89.2% at 
discharge and 99.0% during the follow-up period. 
 
Discussion
This study reports the mid-term (10.9 ± 3.6 months, range: 
1 to 24 months) results of follow-up in 110 children who 
underwent the transcatheter closure of the VSD with the 
Amplatzer VSD Occluder. The VSD is the most common 
congenital heart disease.1, 2, 12 Patients with moderate to large 
VSDs and volume overload of the left ventricle due to these 
defects require the closure of the defect to prevent cardiac 
complications.13, 14 The interventional approach in comparison 
with the surgical approach for the treatment of congenital 
heart diseases is better appreciated by pediatric patients and 
their parents because of shorter lengths of hospitalization, 
avoidance of sternotomy, and fewer complications. The 
Amplatzer VSD Occluder has been proved to have all of the 
mentioned advantages. 
The transcatheter closure of the VSD has rare 
complications such as device embolization to the right or left 
side of the heart, AVB, and femoral artery thrombosis. Late 
complications are rarer, and AVB, late device embolization, 
and hemolysis are described in the literature.
In selected patients who had at least a 5-mm distance 
between the superior rim of the defect and the aortic cusps, 
the Amplatzer VSD Occluder was successfully deployed 
via the retrograde approach.8 The use of specific Amplatzer 
VSD Occluders for the perimembranous VSD has expanded 
the indications for percutaneous closure to cases with only 
1 to 2 mm between the aortic valve and the defect, and the 
rate of successful closure is between 90% and 100%.15-17 
The results of our study of the transcatheter closure of the 
perimembranous VSD with the Amplatzer VSD Occluder 
were excellent: we achieved an occlusion rate of 99.1% 
at follow-up, which is comparable with other reported 
results.15-17 Although some patients had a residual shunt at 
the end of the procedure in our study, only one (0.9%) patient 
had a small residual shunt during the follow-up period. None 
of our patients developed aortic valve regurgitation or valve 
injury. 
One of the common morphologic variations in the 
perimembranous VSD is the presence of aneurysm formation 
in the ventricular septum. This aneurysm formation was 
found approximately in half of our patients. During the 
procedure, we tried to close the true anatomic defect with 
Mid-term Follow-up of the Transcatheter Closure of Perimembranous Ventricular Septal Defects ...
186
The Journal of Tehran University Heart Center
J Teh Univ Heart Ctr 10(4) October 27 2015 http://jthc.tums.ac.ir
the best appropriate device, depending on our judgment 
of the patients and their VSD sizes. In patients with small 
aneurysms, the device was able to cover the defect and 
the aneurysm together. In cases of large defects and large 
aneurysms, to avoid using an oversized device and to 
close the true defect, we implanted the devices within the 
aneurysms themselves. At follow-up during this time, TTE 
demonstrated a small residual shunt in one (0.9%) patient.
The occurrence of complete AVB is the only serious and 
worrisome complication of interventional perimembranous 
VSD closure. In patients treated for percutaneous VSD 
closure, the occurrence of complete AVB can be a late 
complication compared with the surgical approach, in which 
complete AVB usually appears early after the operation.8 
The rates of complete AVB reported in the literature 
vary between 0 and 5%,15-18  although a higher rate was 
reported in one study elsewhere.9 There are no data on the 
mechanisms involved in the occurrence of complete AVB 
following the interventional approach and the percutaneous 
closure of the perimembranous VSD. Complete heart block 
has been reported to occur at any time from a few minutes 
to months after successful and uncomplicated procedures.18, 
19 Currently, because of the high reported incidence of 
complete heart block by this approach, the device is not 
approved for the perimembranous closure of the VSD; 
and device modification, which may result in a reduction 
in external forces exposed onto the conduction system, 
is needed. The occurrence of complete AVB is related 
mostly to the conduction system around the margins of the 
defect; accordingly, both device implantation and surgical 
approach may interfere with atrioventricular conduction 
and induce complete heart block. Larger devices may 
cause more external forces and direct compression trauma 
or promote an inflammatory reaction and scar formation 
in the conduction tissue and give rise to the occurrence of 
complete AVB. This complication occurred in one (0.9%) 
patient with a perimembranous VSD in our series during 
the procedure, which disappeared immediately when we 
removed the device, and in another (0.9%) patient after 
the procedure, which necessitated pacemaker implantation. 
These rates rank among the lowest reported in the literature. 
In our series, the median follow-up was 10.9 months, 
and complete AVB was seen in one patient. Some authors 
have described that an oversized device is a risk factor 
for the occurrence of complete AVB in patients with the 
perimembranous VSD. We believe that case selection 
is vitally important in this complication and we did not 
use oversized devices in our patients. Some authors have 
suggested that the use of steroids could be helpful to 
avoid complete AVB and pacemaker implantation.20-22 
We did not use steroids for the prevention of pacemaker 
implantation in our patients, and need for pacemaker 
implantation in our study population occurred 2 weeks 
later. Nonetheless, we should monitor complete AVB as a 
late event occurring in postprocedural phases during the 
follow-up period. Complete AVB may occur in completely 
asymptomatic patients. The occurrence of complete AVB 
has been reported in patients less than 5 years of age at the 
time of the procedure. Therefore, the percutaneous closure 
of the perimembranous VSD in young subjects must be 
carefully suggested to the patients and their family due 
to the challenging nature of this technique and the risk of 
complete AVB. At follow-up, patients should be routinely 
monitored via ECG in every visit and with the ECG Holter 
if necessary.
Overall, in our study, no early and mid-term major 
complications such as mortality, device embolization, 
arterial complications, hemolysis, and endocarditis 
occurred. We had one patient with complete AVB, which 
ranks among the lowest range in the literature. The results 
of this study demonstrated the efficacy of the transcatheter 
closure of the perimembranous VSD with the Amplatzer 
VSD Occluder both during early and intermediate follow-
up periods.
The most notable limitation of the present study is its 
mid-term follow-up duration; longer follow-up periods are 
required in future studies.
Conclusion
The mid-term follow-up of our pediatric patients 
showed that the VSD closure with the Amplatzer VSD 
Occluder was a very safe and effective method for the 
management of medium to large VSDs. The meticulous 
selection of patients and devices is essential for reducing 
complications, especially complete AVB. Complete ABV 
must be monitored as a late event during long-term follow-
up periods. In our study population, the left ventricular 
dimensions returned to normal. In addition, growth returned 
to the normal pattern in the patients with failure to thrive. 
However, there is always the possibility of the occurrence 
of some complications. More in-depth evaluation of this 
method with a view to reducing the risk of complete AVB 
requires further studies with long-term follow-up. 
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